SEC Eyes Dendreon, Possibly Over Provenge Launch
Dendreon Corp. has recently become the subject of a U.S. Securities and Exchange Commission investigation that the biotechnology company believes could be related to various class actions over the release of...To view the full article, register now.
Already a subscriber? Click here to view full article